The 10 Most Recommended Pharma & Life Sciences Solution providers in 2019

VOL 04 

April 2019 

ISSUE 01 

The 

10 Most 

Recommended 

Pharma 

& 

Life Sciences 

Solution 

providers in 2019 

Sarjen 

Systems 

Promoting Indian Pharma 

Research on Global Scene 

Nikur Mody 

Founder

From The 

Editor 

RAPIDLY 

EVOLVING 

INDUSTRY 

PHARMA 

& 

LIFE 

SCIENCE 

THE OUTLOOK

decade ago, the global industry of pharma and life 

Ascience, which was of 390 billion USD, has now crossed 1 

trillion USD and still it is marching forward majestically. 

“One of the biggest challenges to medicine is the incorporation of 

information technology in our practices” said Samuel Wilson. 

Today, to remain competitive in this dynamic environment, the 

Pharma and Life Sciences organizations are quickly adapting 

and responding to the on-going changes in market conditions, 

customer requirements, and government and industry 

regulations. The giant companies are controlling the one-third of 

the market and producing revenue around in billions of USD, 

while many large numbers of start-ups and SMBs are competing 

to get their share of pie, and benchmark their existence in this 

fiercely competitive domain. 

Predicting the future for better analysis of patient adherence and 

improving time to market remains the key element of success. 

Accessing, analysing and managing the vast volumes of data 

have been a very critical task to pharma and life sciences 

companies, as they improve business efficiency and 

performance. 

And, this is where this ‘Next Generation’ architecture the Big Data 

and Analytics are helping to improve the efficiency and the 

development processes. 

On the concluding note, today the world is leveraging 

technology intelligently to gain competitive advantage. The 

profound market research is done in order to provide a plethora 

of solutions. With changing times, the industry is uncovering 

innovations that are revolutionizing the current product lines and 

unfolding infinite opportunities for betterment of the manking. 

Shruti P. Jambhale 

Shruti P. Jambhale

C o n 

Cover Story 10 

Sarjen Systems 



cxo 

24 

18 

Interview With Insights Success 

Accurex Biomedical 

Pioneer in Manufacturing 

and Marketing of In-vitro 

Diagnostic Reagents 

32 

Digitalizing 


5 ways in which Digitalization 

is Transforming Healthcare 

and Pharma Industry 

Healthcare 

Predictions 

Future Predictions of 

Electronic Health Records, 

2019 and Beyond

t e n s 

Ashish Life Science 

Delivering Highest Quality 

Veterinary Medicines 

at Economical Price 

22 

Fermenta Biotech Ltd 

Discover | Develop | Deliver 

30 

Nucleome Informatics 

Unraveling the Genomes 

for a Better Future 

38 

Articles 

26 

34 

Medicine 

World Insights 

10 Medicines that 

Changed the World 


Trends 

Top Pharmaceutical Trends 

to Watch Out in 2019 

C o n t e n s

Editor-in-Chief Pooja M. Bansal 

Managing Editor Devasish Kanojiya 

Executive Editor 

Shruti P. Jambhale 

Art & Design Head Amol Kamble 

Associate Designer Poonam 

Art & Picture Editor Rahul Kavnekar 

Co-designer 

Mayur Koli 

Business Development Manager 

Akansha Garewal 

Sales Executives Rutuja, Kaustubh, Shraddha, Joan 

Technical Specialist 

Amar, Pratiksha 

Digital Marketing Manager Prashant Chevale 

SME-SMO Executives Swati, Manoj 

Circulation Manager 

Tanaji 

sales@insightssuccess.com 

April, 2019 

Corporate Ofces: 

Insights Success Media and Technology Pvt. Ltd. 

th 

Off. No. 513 & 510, 5 Flr., Rainbow Plaza, Shivar Chowk, 

Pimple Saudagar, Pune, Maharashtra 411017 

Phone - India: +91 7410079881/ 82/ 83/ 84/ 85 

Email: info@insightssuccess.in 

For Subscription: www.insightssuccess.in 

Insights Success Media Tech LLC 

555 Metro Place North, Suite 100, 

Dublin, OH 43017, United States 

Phone - (614)-602-1754 

Email: info@insightssuccess.com 

For Subscription: www.insightssuccess.com 

Cover Price : RS. 150/- 

Follow us on : www.facebook.com/insightssuccess/ https://twitter.com/insightssuccess 

Copyright © 2019 Insights Success Media and Technology Pvt. Ltd., All rights reserved. The content and images used in this magazine should not be reproduced or 

transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights Success Media and Technology Pvt. Ltd. 

Reprint rights remain solely with Insights Success. Printed and Published by Insights Success Media and Technology Pvt. Ltd. 

RNI NUMBER: MAHENG/2018/75953

1T 

HE 

MOST RECOMMENDED 

PHARMA & 

L FE SCIENCES 

SOLUTION PROVIDERS IN 2019

harma and life sciences companies are taking important steps to 

Padvance their business processes and drive greater efficiencies. 

The industry will embrace transformation initiatives at a faster 

pace in coming years, across multiple functional areas, including 

commercial, clinical, regulatory, and quality. 

In product development, companies are focused on streamlining 

end-to-end processes to speed time to market and maintain compliance. 

For commercial teams, driving smarter engagement with customers 

remains a core focus as they launch more specialized products. 

This month, Insights Success has come up with a very contemporary topic 

and has dealt under the issue of “The 10 Most Recommended Pharma 

& Life Sciences Solution providers in 2019”. Here we have tried to 

focus on the different business portfolios with unique service solutions, 

and Sarjen Systems Pvt. Ltd. has grabbed our attention most to become 

the Cover story of this magazine. This brand is one of the best when 

comes to the Pharma and Life Science Solution Providers. 

A Look into 

the Pharma 

& 

Life Science 

Canvas 

We have also focused on different companies those have come up with 

unique solutions. Ashish Life Science Pvt Ltd offers a range of cutting 

–edge veterinary products with the world-class manufacturing 

infrastructure and relationship driven approach. Fermenta Biotech 

Limited is a multifaceted organization with a high degree of focus on 

research, development and product delivery in the field of biotechnology, 

pharmaceutical and environmental solutions. Nucleome Informatics 

Private Limited plays a major role by providing Genomics and 

Bioinformatics analysis support. 

Alongside, the companies like Avesthagen Limited, Global Calcium 

Private Limited, Infionic Inc., Kare4u Healthcare Solutions Pvt., NecLife, 

Syngene have also been featured in the listing of “The 10 Most 

Recommended Pharma & Life Sciences Solution providers in 2019”. 

The interview with Insights Success, Abhinav Thakur gave us glimpses 

on his brand Accurex Biomedical Pvt. Ltd. It is one of the top 3 

manufacturers of quality Clinical Chemistry Reagents and Urinanalysis 

Test Strips with over 34 years of expertise in this area. 

This magazine also includes leaders’ thoughts as well. Sudip Chhatui, 

the VP- Business and Operations discuss on the “5 ways in which digital 

is transforming healthcare and Pharma industry” and Kumar 

Subramaniam, the Founder & CEO of 75Health highlights on the 

“Future Predictions of Electronic Health Records, 2019 and Beyond”. 

The editor’s thoughts are also part of this magazine where they have 

researched on contemporary topics like Top Pharmaceutical Trends to 

Watch Out in 2019 and 10 Medicines that Changed the World. 

So have a look at the magazine and get the Insights of the Pharma and 

Life Science Solutions!

1T 

HE 


PHARMA & 

L FE SCIENCES 

SOLUTION PROVIDERS IN 2019 

Sarjen 

Systems 



COVER STORY

Nikur Mody 

Founder

Today, everyone is well aware 

that Pharma Research is the 

sector where there are only a 

few predominant players. There are 

many companies, which are embracing 

the changes and creating a niche in the 

pharma & life science sector. Sarjen 

Systems is one such company which is 

providing affordable solutions by 

supporting and promoting pharma 

research – a small step to bring Indian 

pharma and pharma research on the 

global scene. 

With the Vision of “Having a 

world-class organization with 

operational excellence and global 

reach”, Sarjen Systems has always 

maintained standards to excel with 

minimum fuss following on the 

Mission of “Spreading the power of 

business technology solutions to 

customers across the globe; adding 

value to their businesses. And, 

encouraging support for our employees 

who in turn would provide exceptional 

service to the customers”. 

‘ 

DEVELOPING 

SOLUTIONS 

USING CUTTING-EDGE 

TECHNOLOGY 

& 

STRETCHING 

THE LIMITS TO 

GET THE BEST 

The Outset of the Sarjen Systems 

Nikur Mody is the Founder of Sarjen 

Systems and ever since, he has always 

been interested to strike out, pursuing 

that seed of an idea with a zealous 

rage. Coming from an IT background, 

his interests led him to think of 

introducing simplified approach to 

software development. 

In 90s, a lot of business software were 

entering into the market and gaining 

momentum to get recognized. By the 

time, Mody realized that there were 

ongoing gaps between business 

expectations and technology 

enthusiasts who would understand 

those expectations very differently. 

And, amazingly, Sarjen Systems was a 

result of this ideology and was founded 

in the late 90s to offer technology 

solutions understanding and serving 

precise business expectations. 

It became easier for Sarjen Systems, to 

meticulously study customer processes, 

variations in them from customer-tocustomer, 

and employ a dedicated team 

of business technology consultants. Its 

primary function is to fulfill customer 

expectations and deliver that last-mile 

customization to achieve significant 

improvement in work efficiency. 

Leader, Motivator, and a Mentor 

Nikur Mody is a visionary, at the 

nucleus of the team of brilliant experts, 

guiding and providing directions to the 

organization through the emerging 

industry and technology changes and 

evolving methodologies. This has 

helped Sarjen Systems start the next 

“great big” walk, playing a key role in 

shaping the corporate functions of 

business development as well as 

finance. 

Nikur has completed an MBA in 

International Business and Finance 

after finishing his Bachelor’s in 

Engineering with specialization in 

Computer Technology. His innovative 

but practical approach has helped 

Sarjen Systems’ customers to realize 

value proposition through software 

solutions. Having worked with all 

functional areas at grass root level, has 

helped in envisioning innovative 

projects with great detail. Prior to 

Sarjen Systems, he has worked with IT 

companies like L&T Information 

Technology and Mastek Ltd. in

strategic planning where he engaged 

his technology and engineering skills 

to solve significant corporate 

challenges. 

Notable Software Solutions 

Since its founding, Sarjen Systems has 

stood out through its own unique 

business style. And, has been known to 

architect, design and develop 

proprietary technology stack with 

enormous careful thought and 

consideration. 

The product story includes three 

flagship products which are an 

evolution of solutions progressing to 

address client demands. It starts with 

Sarjen Systems developing 

PharmaNET for supply chain and sales 

‘n distribution, for sales force 

automation – FFReporting, and then 

FForce – a Field Sales Excellence 

platform. 

Some other unique solutions are: 

KnowledgeNET - a global Drug dossier 

publishing and lifecycle management; 

RIMS for regulatory information 

management. 

ProcessXE - an MES in the form of 

pharmaceutical manufacturing 

automation with eBMR, Dispensing 

and logbooks. 

QEdge - an automated enterprise-wide 

quality management (eQMS) for 

quality processes to maintaining 

training records and eLearning to 

document control and management for 

controlled processes and practices. 

PvEdge - Drug safety database for 

pharmacovigilance of drugs, vaccines, 

devices, clinical trials, veterinary 

vigilance – incorporated with signal 

detection and literature automation. 

BizNET - Paperless clinical trial 

management which can cover several 

different types of trial protocols, study 

types. 

Whereas consulting on SAP 

deployment, Computer System 

Validations (CSV), Data analytics and 

AI & Machine Learning (ML), 

extending applications as Mobility 

solutions are Sarjen Systems’ forte. 

The Plus Points 

Starting with the sales and distribution 

solution, PharmaNET and then 

integrated it with ERP to give a robust 

boost to have some vital complexities 

outside of ERP, Sarjen Systems kept on 

adding one solution after another in its 

‘ 

SARJEN 

SYSTEMS 

HAS AN 

AMALGAMATION 

OF TECHNOLOGY 

AND INDUSTRY 

KNOWLEDGE 

CATERING 

SOLUTIONS WITH 

SIMPLICITY, EFFICIENCY 

& 

VISIBILITY TO 

AN ENTERPRISE

solution list. In this broad spectrum, 

mobility solutions on one end and on 

the other end, developing and 

implementing solutions for digital 

transformation of clinical research 

organizations, drug safety database, 

enterprise-wide quality management 

and many more. At the core of Sarjen 

Systems’ solution implementation 

success, there is a flexible delivery 

approach where it efficiently merges its 

domain expertise with the proprietary 

technology stack. All the products can 

be 

‘ 

easily integrated with industry 

CONSTANT 

GREATER 

GOALS 

ARE THE WAY 

TO KEEP 

MOMENTUM 

GOING AND 

SUCCEED 

standard enterprise applications. Also, 

the project management and consulting 

teams seamlessly execute integrating 

of projects ensuring high throughput. 

The solutioning for pharma and life 

science domains was the precursor of 

implementing processes and 

maintaining high quality standards 

with continued improvements. This 

would help in ensuring that there were 

no defects or bugs in delivery, 

documentation and maintaining 

all-around quality standards. Sarjen 

Systems provides solutions and 

services across several industry 

domains including Pharmaceutical, 

Healthcare, Life sciences, FMCG, and 

few others; complying with global 

regulatory guidelines. 

Sarjen Systems’ USP 

· Expertise in Pharma and Life science 

domains 

· Proprietary Technology Stack · 

Global Exposure/Presence 

· Complete solution basket – from 

Drug Development to Sales 

· Expert on cGxP and Regulatory 

guidelines 

· Solutions compliant with Part 11 

(Annex 11, EMA and 21 CFR Part 

11, US FDA) and global guidelines 

· Multiple Licensing models to suit 

enterprise needs 

Unlocked Milestones 

Getting ISO 9001:2008 certification 

was the natural progression and it gave 

way to very structured quality 

management integrated with Sarjen 

Systems’ SDLC. Then, upgrading to 

risk and opportunity based ISO 

9001:2015 standards to achieve and 

maintain control, and continual 

improvement for processes, products 

and services. Continuing them forward 

ensures structure, process-driven 

approach for seamless quality. Also, 

implementing compliant GxP 

computerized systems using GAMP5 

driven risk-based validation for part 11 

compliance. 

Dynamic project management with the 

right set of people to develop solutions 

using cutting-edge technology, 

stretching the limits to get the best, 

achieving timelines in the budget, 

rising to the challenge of defining 

milestones, planned commitments and 

deliverables, maintaining quality, 

tracking progress and overall 

strategizing the various stages of 

software development is Sarjen 

Systems’ highlighting forte. 

Rewards and Recognitions 

Sarjen Systems was recently shortlisted 

as “Best Software Company” @ 

Vibrant Gujarat Technology Summit. 

Sarjen Systems is a Microsoft Gold 

partner. Also, NASSCOM and Gesia 

member. Their core team members 

have been invited to speak at numerous 

events on various topics. They have 

recently hosted a NASSCOM event. 

A Piece of Advice 

“One must focus on deep domain 

expertise and user-centric design with 

persistence to adapt, adopt and 

innovate. Small and meaningful 

improvements will lead to hugely 

differentiating product in the long 

run.” – states Nikur Mody. 

Exploring Market Leadership 

Sarjen Systems’ ongoing adaptation of 

AI, ML, Blockchain and Deep 

Learning has brought impactful change 

across its solutions. These 

technological advancements of now 

and tomorrow, would not only improve 

overall efficiency and inculcate good 

practices but also indirectly contribute 

to better and greater patient safety. 

Sarjen Systems is all set to continue its 

habit of innovations by embedding 

new technologies and achieve a higher 

position as a leading software solutions 

provider, globally.

KNOW US BETTER 

• Founded Year: 

1998 

• Headquarter in: 

Ahmedabad, India 

• Major Operation Centers: 

Support offices in Mumbai, 

India; London, UK and 

Durham, USA 

• Total Number of Clients 

Served & Countries 

Served: 

100+ clients in 50+ 

countries 

• Our Tagline: Pioneering 

digital transformation for 

Indian Pharma research 

• URL: www.sarjen.com 

‘ 

WE ARE 

A WORK CULTURE 

CREATING 

IDEA FLOWS MIND VERY EASILY 

OUT OF 

WHERE

Read it First 

Subscribe today 

Yes I would like to subscribe to Insights Success Magazine. 

Global Subscription 

Name : 

Address : 

Date : 

Telephone : 

Email : 

City : State : Zip : 

Country : 

Cheque should be drawn in favour of : INSIGHTS SUCCESS MEDIA AND TECH PVT. LTD. 

CORPORATE OFFICE 

Insights Success Media and Technology Pvt. Ltd. 

th 

Off No. 513 & 510, 5 Flr, Rainbow Plaza, Shivar Chowk, 

Pimple Saudagar, Pune, Maharashtra 411017. 

Phone - India: 020- 7410079881/ 82/ 83/ 84/ 85 

USA: 302-319-9947 

Email: info@insightssuccess.in 

For Subcription: www.insightssuccess.in

Interview with Insights Success 

Accurex 

Biomedical 

In today’s fast paced world, disease is 

not taken care of until body shows 

symptoms. Can high quality healthcare 

be delivered if patient’s physician is 

hurried, cold or uncaring? That’s why 

many of the companies are innovating new 

technologies, new processes for timely 

diagnosis and treatment of diseases. 

Pioneer in Manufacturing and 

Marketing of In-vitro 

Diagnostic Reagents 

In an interview with Insights Success, Abhinav Thakur, 

Managing Director at Accurex Biomedical Pvt. Ltd. has 

shared some insightful views and highlighted the influences made 

by their company. The company is one of the top 3 manufacturers 

of quality Clinical Chemistry Reagents and Urinanalysis Test 

Strips with over 34 years of expertise in this area. 

INTERVIEW WITH INSIGHTS SUCCESS 

1. Share with us the motivating factors that led towards the inception of company? 

I was studying in the USA when unfortunately, my father passed away prematurely. I came back to 

India to run the company for my family. 

At that point of time motivation for me was survival of the family business. 

Now the motivation for me is to grow the company so I can have an impact on the economic 

development of our country. I strongly believe that strong economic development is the antidote the 

poverty. 

2. Brief us about the goal, vision and mission of the company; it has set to mark its exceptionality in 

future. 

We are in the medical diagnostics industry and impact the lives of humans. 70% of medical 

decisions are made based on medical diagnostic reports. Hence our mission is to help save lives by 

providing accurate and precise medical diagnostic solutions to pathology laboratories. 

Our vision is to be one of the Top medical diagnostic companies of India by 2025. 

3. Which is you flagship product? Tell us something about that. It would be great if you provide us 2-3 

notable feedbacks from of renowned clients/business leaders regarding your products/services. 

The most common test in any pathology lab is blood glucose. Diabetic patients are aware about their 

blood sugar levels and blood glucose is also checked at home by many diabetics. 

If there is an error I the blood glucose report the chances of the patient questioning the report are 

very high when compared to other tests. 

If the patient finds out the results provided by the lab are inaccurate by testing in another lab or at 

home, then the lab loses a customer and its reputation. 

Consequently, blood glucose is one of the test on which the reputation of a lab depends. 

18 | | APRIL 2019

Abhinav Thakur 

MD 

APRIL 2019 | 

| 19

Accurex today is the largest supplier of blood glucose 

reagents in the country because of the quality of our 

reagents. 

This proves that our quality of reagents is the best in the 

country. 

4. Tell us about the services you provide through your 

venture (apart from your flag-ship one). 

We also provide medical diagnostic instruments. 

5. What is the uniqueness of your products and services as 

compare to your competitors? Kindly elaborate in 

detail. 

Our company was established in 1984. Since we have 

been in the market for over 34 years we have build a 

strong brand in the market. If it was not for the quality 

of our products it would not have been possible for us 

to survive in the market for over 34 years. 

Hence quality of our reagents and resulting brand for 

the last 34 years is our competitive advantage. 

6. Brief us about the Founder/CEO of the company and 

the major contribution of him/her towards the 

development of the company. 

My father, Mr. Anil Thakur was the Founder & 

Ex-Managing Director of Accurex Biomedical Pvt. 

Ltd. He was an excellent visionary. Under his 

leadership, Accurex had launched various innovative 

products and marketed them with innovative strategies. 

He established Accurex as a Customer-Oriented 

organization, and launched the 24 x 7 module for all 

Accurex customers to log on their complaints/queries 

24 hours a day; 7 days a week - the first-of-its-kind in 

India. 

Mr. Thakur took Accurex to international platforms 

through Medica, APCCB and various other 

International exhibitions and conferences. His 

contribution towards Accurex for the last 20 years was 

enormous. Unfortunately, Mr. Thakur passed away on 

25 January, 2004. However Accurex will continue to be 

guided by his ideals and vision. In the near future, 

Accurex will achieve a leadership position in the 

Asia-Pacific region which was his dream. 

7. What are the positive developments going on in the 

Pharma & Life Sciences Solution provider company? 

Point-of-care testing (POCT), or bedside testing is 

defined as medical diagnostic testing at or near the 

point of care—that is, at the time and place of patient 

care. This contrasts with the historical pattern in which 

testing was wholly or mostly confined to the medical 

laboratory, which entailed sending off specimens away 

from the point of care and then waiting hours or days to 

learn the results, during which time care must continue 

without the desired information. 

POC testing is getting popular in the medical 

diagnostic industry. 

Through POC testing the lab tests are available at the 

doctors and patients at home. This is convenient to the 

patient. 

8. Your advice to budding entrepreneurs? 

Four mantras: 

1. Good Governance: Never compromise on your 

ethics. Sooner or later you will have to pay the 

price. Reputation built over years can be 

destroyed in hours if you compromise on ethics. 

2. Empower your team. Don’ 

t dictate your terms to 

the team but involve your team in the decision 

making process to get ownership. 

3. Build a competitive advantage in your business 

or you will become a commodity soon and loose 

your market share. You need to keep innovating 

to build your competitive advantage. 

4. Purpose: You need to build a strong purpose for 

your business. If you don’ 

t have a strong 

purpose then you will give up in the difficult 

times. Money cannot be the only purpose 

because if money is the only purpose then it will 

be short lived and you may end up taking 

short cuts. 

9. What the company desperately wants to achieve in the 

next few years? 

In the next few years we want to build our foundation 

strong so we can raise funds and grow to achieve our 

mission and vision. 


Ashish Life Science 

Delivering Highest Quality Veterinary Medicines at Economical Price 

Meet the Profound Founder 

Raujesh Agarrwal, the Founder of Ashish Life Science 

Pvt. Limited, has completed PG in Family Managed 

Business. He is responsible for deploying the company’s 

strategic vision and developing business alliances as well 

as building the management team. He has been actively 

involved in sales & marketing of the company products 

all over the world. Over the period of time, he appointed 

distribution & marketing channel in over 60 countries. 

Idea behind ‘ALS’ 

After travelling to many countries, Raujesh realized the 

potential of Indian veterinary medicine. He recognized 

the huge business prospective for Animal health products 

in International markets. Seeing the vision and growth of 

the industry he decided to start manufacturing and 

exporting veterinary products. 

Raujesh Agarrwal, Founder 

Ashish Life Science Pvt. Ltd. (ALS) is 

established since 2002. Since inception, it is 

taking efforts to deliver significant value to its 

customers by understanding their needs and innovating 

to offer the right choice of products. Over the years, it 

has built up a reputation for reliability and trust between 

company and its customers. 

ALS’s entire team is consistently evolving to meet its 

customers’ needs across the Globe. It offers a range of 

cutting –edge veterinary products with the world-class 

manufacturing infrastructure and relationship driven 

approach. 

“We pride ourselves on personal service, good working 

relationships, and satisfying our customers wherever 

they may be.” says Raujesh Agarrwal, the Founder. 

“We believe animals have been catering to service of 

mankind and it is our duty to reciprocate back.” –states 

Raujesh. 

World-Class Quality Products 

The company has therefore, developed a strong focus on 

‘Animal Healthcare’. The provided quality is beyond the 

horizon of any negotiation. Therefore, world-class 

manufacturing facility has been set up that could meet 

stringent cGMP Guidelines of any regulatory body 

including World Health Organization. The company 

strictly follows cGMP in all aspects of production and 

distribution activities. Also, the manufacturing facility is 

approved by various health authorities for supply of 

veterinary medicines. 

Inclusive Services 

ALS exhibits high diligence at every level and function. 



PHARMA & 

L FE SCIENCES 


Adherence to quality, best-in-class manufacturing 

practices, highest level of laboratory certification and 

high service standards have enabled it to build lasting 

relationship across the globe. 

“As India is strong on human pharmaceuticals; 

therefore, we saw an opportunity for pharmaceutical in 

the Animal space and decided to totally focus on animal 

products.” states Raujesh. 

Rising above the Horizon 

Behind the meteoric rise of ALS, there is a team of 

committed individuals. The team of ALS comprises of 

dedicated professionals who believe in learning, empathy 

and innovation. The entire team is relentlessly and 

passionately working towards the advancement of 

animal care. 

ALS operates across the entire spectrum of therapeutic 

segments – Antiparasitics, Ecoparasiticides, NSAIDs, 

Antibiotics, Antifungal, Antiprotozoal, Tonics and 

Neutraceuticals to name a few. Besides, it also offer all 

dosage forms – bolus, tablets, powder, suspensions, 

solutions, oral paste, injectable and spray & ointments 

ensuring that its clients also have an ease and 

effectiveness of administrations. 

Notable Achievements 

Ashish Life Science has won the “SME Business 

Excellence Awards 2014”, presented by D&B, The 

Times Group and Federal Bank. Also, it has been 

recognized as “India’s small Giants” by India SME in 

2014. Furthermore, Raujesh was interviewed by ET now 

after ALS was recognized as an emerging “Pharma 

Company in micro segment”. 

Additionally, ALS has won the prestigious “Top 100 

SMEBOI Awards” (achievers of 2012), the “Top 100 

SMEBOI Awards” (Achievers of 2013) and the “ECGC- 

D&B- Indian Exporters Excellence Awards 2015 – Best 

manufacturing Exporters” Award along with the Golden 

Maharashtra MSME’s “Manufacturing Summit 2015 

Award”. And, it has been featured in the well-known 

“Dollar Business magazine” in 2016. 

1T 

HE 

We believe that our 

customer's customer 

is our customer 

and satisfaction 

of these customers 

is our responsibility 

as well, and, 

we believe in 

delivering Value 

Founder’s Piece of Advice 

“Today, there is strong awareness by people about 

generics. People have started questioning the cost of the 

product. Thus, this is forcing companies to reasonably 

price their products.” says Raujesh. Furthermore, he said 

“It’s all about Vision – Passion – Commitment”. 

Rock-solid Future 

The company is having crystal-clear vision and thus, 

gearing up to adopt the future trends. It has established 

its name in the international market and will continue to 

surpass the expectations of the customer and always 

improve and deliver highest quality at economical price 

on timely basis. 

| 23 

APRIL 2019 |

Digitalizing Pharma 

Author 

ABOUT THE 

Sudip Chhatui –VP, 

Business and Operations at 

Curofy 

Sudip hails from Kolkata 

NSIT, Delhi Alumni. He was 

the first person in the 

Curofy Marketing team, 

who joined before the 

launch of the Curofy app. 

Initially set up and led the 

growth team and is now 

leading the Business 

development team Curofy. 

He is a startup enthusiast. 

And, he is one who loves 

traveling. Also, a Real 

Madrid fan. 


5 

PHARMA 

echnology is changing every industry in significant 

Tways. No one can dispute technology’s ability to 

enable us all to live longer and healthier lives. 

From surgical robots to “smart hospitals,” the digital 

transformation is revolutionizing pharma and healthcare 

industry. 

While talking about digitalization, a point which needs to 

be clarified is that it isn’t just about automation of process 

or job or even new technology. It is much bigger and more 

fundamental than that. Digital transformation is about using 

digital technologies and data to fulfil the need of the 

consumer. 

Data visualization to increase accessibility 

WAYS IN WHICH 

DIGITALIZATION 

IS TRANSFORMING 

HEALTHCARE AND 

INDUSTRY 

Financial transparency: 

Technology helps people in getting information about 

healthcare expenses. Till now, if the patient was getting 

treated, it was often unclear whether the procedures being 

done are actually necessary or not. But, now the patients 

and their family are well aware of the treatments. There’s 

also a lack of consistency for health care treatments, the 

same services and procedures vary in cost from state to 

state, sometimes even from one hospital to the next. In 

many cases, patients don’t know how much a procedure 

costs until it’s done and they’ve received the bill. 

Healthcare cost sometimes leads to personal bankruptcy. 

Digital transformation is helping the system to improve the 

overall patient experience. 

Data visualization isn’t just any art, it’s grounded in real 

results and industry findings. With the new technology, the 

way people access and process information are changing. 

For example, smart health monitors that can collect 

personalized, real-time data, encouraging healthier 

lifestyles help in gathering more lifestyle data, and medical 

records. Comparing the responses of patients with 

similarities in DNA, medical histories and lifestyle can 

allow us to understand health risks and the impact of 

different treatments. This sharing of data-based intelligence 

if done in a tangible and accessible way, not just helps the 

scientifically-minded people but also helps the border 

audience. 

Access to a wide range of medical products 

The medical product information is easily accessiable 

nowadays, it is no more limited to pathways of pharma 

companies and the secrecy no longer exists. Information 

about every medicinal product is available on the internet. 

Patients and consumers can easily find various ways to cure 

there condition through the internet. They can even find the 

alternatives to drugs without spending a penny. 

Digitalization streamlines the process for efficiency: 

Future-forward technologies like AI that can make some of 

the major complex kind of decisions using in-depth data 

and analytical calculations are transforming strategic 

processes as we know them. 

Increasing channel of communication: 

Earlier if a patient had any healthcare concerns they used to 

rush to the hospital. However, with a growing digital 

presence, patients now explore the internet for hospital 

sites, e-mailers to connect to the doctor. Other than this, 

patients have online access to medical records which they 

can share with their doctors. 

Digital transformation is an ongoing journey that requires 

putting the consumer at the centre of your business. It has 

created a whole new realm of possibility for the consumer, 

specifically with the advent of smartphones and their 

applications (apps). Smartphone apps are now considered 

helpful in enhancing patient education, facilitating 

communication and patient engagement. 


| 25

Medicine World Insights 

Penicillin 

01 

10 Medicines 

that Changed 

the World 

It was discovered in 1928 by Scottish scientist 

Alexander Fleming. Antibiotic, People began using 

in 1942 to treat infections and it is used to treat 

infections caused by certain susceptible bacteria. 

Ether/General 

Anesthesia 

03 

The use of anaesthesia can be traced back to 

ancient civilizations when opium and other natural 

substances were used for the purpose. The first 

public demonstration of the use of Ether as an 

anaesthetic was done in 1846 by William T.G. 

Morton. Diethyl Ether or Ether is an organic 

compound holding anaesthetic properties and 

was widely used during surgeries until 2005. 

02 

Insulin 

A natural protein, it needs to be administered as 

medicine for diabetic patients. First used in 1922 

by Frederick Banting, Charles Best and James 

Collip. It is used to treat diabetes and 

complications arising due to it and used along 

with glucose to treat high blood potassium levels. 

Oral 

Contraceptives 

04 

Oral Contraceptive pills are a method of hormonal 

contraception for birth control taken by women. In 

1950 Margaret Sanger jotted down her research 

findings to develop a birth control pill and in 1960, 

the first pill was approved. Some pills contain both 

estrogen and progestin while some contain only 

progestin. They prevent fertilization by inhibiting 

ovulation and thickening cervical mucus and 

depend on the user's adherence to the dosage. 

05 

Aspirin 

A non-steroidal anti-inflammatory drug, 

acetylsalicylic acid (ASA) was first created in 1853 

by French Chemist Charles Frédéric Gerhardt and 

rechristened as Aspirin by Bayer for commercial 

use. It is used to treat pain, fever and 

inflammation in general and used specifically in 

case of heart attacks, and certain types of cancer. 


Mechlorethamine 

06 

Also known as Chlormethine and HN2 is a 

cytotoxic chemotherapy agent derived from 

mustard gas. Once used in warfare, their medical 

utility was first established by a team led by 

Cornelius P. Rhoads. Its derivatives are used to 

treat cancer and lymphoid malignancies like 

Hodgkin's disease, prostate cancer and 

leukaemia. 

07 

Morphine 

Chlorpromazine 

08 

A pain medication extracted from plants which 

belong to the opiate family. First isolated during 

the years 1803-1805 by Friedrich Serturner and 

commercially available in 1827. It acts on the 

central nervous system (CNS) to suppress the 

feeling of pain and is used to treat chronic, acute, 

myocardial and labour pain and can be 

administered orally or injected. 

It was discovered in 1950 by chemist Paul 

Charpentier and was later produced as the first 

antipsychotic medicine. Commonly marketed 

under the name of Thorazine it is used to treat 

psychotic disorders like schizophrenia, Bipolar 

disorder among others. 

09 

Statins 

Antiretroviral 

10 

Statins are a class of lipid-lowering medicines 

that effectively reduce LDL cholesterol. 

Commonly sold as atorvastatin under the trade 

name Lipitor among others, it was first isolated by 

biochemist Akira Endo and approved for medical 

use in 1996. It is used to prevent cardiovascular 

diseases and abnormal lipid levels. 

Multiple Antiretroviral Medicines are used to 

manage HIV/AIDS during the Antiretroviral 

Therapy. Taken in combination, these drugs 

prevent the growth of the virus to slow down and 

control the disease. The therapy first started as a 

solution to the dreaded disease in 1996. 

Sneha Sinha 

Editor 


| 27

Fermenta Biotech Ltd 

Discover | Develop | Deliver 

Himachal Pradesh and was followed by another in 2011 at 

Dahej, Gujarat. Both the units are certificated by global 

accreditations. Aligning with world-class standards, a 

state-of-art R&D center is located at Thane that adds glory 

to FBL. 

Today, it is the only manufacturer and supplier of Vitamin 

D3 (Cholecalciferol) in South-East Asia and shares the 

stage with a few manufacturers at the global platform. 

Having a dominant presence over fifty countries and 300 

global customers, FBL exploits its experience to create a 

worldwide distribution network for pharmaceuticals, dietary 

and nutritional supplements, food, feed veterinary and 

rodenticides. 

Prashant Nagre, CEO 

Nutrition and Preventive Health has taken gigantic 

leaps over the last decade. Emphasizing on 

creating an environment-friendly, sustainable 

world, the global nutraceutical industry is set to be a 

$578.23 billion industry by 2025 as per a report by 

ASSOCHAM. 

Conceptualized in 1986, Fermenta Biotech Ltd (FBL) is 

one of the leading entities within the Indian sub-continent 

that caters to this niche segment. This excerpt illustrates the 

successful voyage of FBL over the years, along with 

showcasing the unique products and services while giving a 

glimpse of an adroit leader - Prashant Nagre, the CEO. 

Inception Saga – Going Down the Memory Lane! 

FBL, incepted under the auspices of Duphar-Interfran Ltd 

(now known as DIL Ltd.), is the brainchild of late Mr. 

Vasant Kumar Datla. Starting the journey from 1986, FBL 

has stamped its presence across the globe and created 

countless milestones and continues to march forward. In 

1987, FBL’s first manufacturing unit came up in Kullu, 

Marquee Products & Services 

Vitamin D3 is the flagship product of FBL and is also its 

largest portfolio in terms of business. Additionally, it has 

amassed expertise in integrated biotechnology solutions viz. 

enzymes as well as an Environmental Solutions business 

vertical focusing on waste management through a blend of 

biotechnology and engineering acumen. 

Vitamin D3 

FBL pioneered the use of proprietary technology to 

manufacture Vitamin D3 in India. It addressed the growing 

need for its products across a wider range of applications in 

the food, pharmaceuticals, dietary & nutritional 

supplements, feed, veterinary and rodenticide segments. 

Biotechnology 

As a pioneer of Penicillin G Amidase (PGA), FBL has 

commercialized next generation PGA enzyme technologies 

for Amoxicillin, Ampicillin, Cephalexin, and Cefadroxil. 

The company offers improved CAL B Lipase catalysts that 

can be used for a plethora of applications. 

FBL has evolved as a dependable technology-driven partner 

enjoying customer trust irrespective of project size, phase, 

and complexity. Embracing innovative technologies have 

enabled FBL to incorporate the latest, eco-friendly 

manufacturing practices, along with addressing sectors 

comprising the pharmaceutical industry, fine chemicals, 

bio-plastics and cosmetics. 



PHARMA & 

L FE SCIENCES 


1T 

HE 

Environmental Solutions 

FBL, a pioneer in enzyme technologies, offers integrated 

biotech as well as engineering solutions that address 

environmental issues. FBL’s tailor-made platform 

technologies provide unique waste water management and 

treatment advantages. 

Apart from its proprietary bio-product, Fermsept, FBL also 

offers Engineering Procurement and Construction solutions 

for a range of applications: encompassing integrated 

solutions for sewage treatment plants and effluent treatment 

plants. 

Steering the Ship Ahead 

Prashant Nagre, CEO, has been associated with FBL for 

almost a decade, leading strategy and overseeing day to day 

operations of all three business verticals viz. Biotechnology, 

Pharmaceuticals and Environmental Solutions. He also 

focuses on further building and developing the various 

strengths of FBL i.e. Manufacturing, R&D and allied 

activities. He forms a core member of the product 

development team and is also responsible for creating and 

nurturing large business account relationships. Known for 

his meticulous planning skills, Prashant adds impetus to 

timely deliveries of products, quality orientation and human 

resource development within the company. 

Awards and Accolades 

In its endeavor to deliver excellence in services, FBL has 

been bestowed with numerous awards and recognitions that 

exemplify its presence as a significant player in the 

industry. Few of the prized achievements are listed below: 

• India Pharma Awards 2018 

o Excellence in CSR for companies with turnover 

less than INR 500 Cr. 

o Pharma International Excellence 

o Excellence in Export Promotion 

• Hindustan Times Thane Ratna Award 2019 – Healthcare, 

Pharma and Biotech Manufacturing 

• World HRD Congress Awards 2018 

o National Best Employer Brands 

o Business Leader of the Year – Mr. Prashant Nagre 

o Top 101 HR Minds – Mr. V.K. Raveendranath, 

General Manager – Human Resources 

• Pride of Maharashtra Award 2019 for Best CEO of the 

Year in Manufacturing – Pharmaceuticals – Mr. Prashant 

Nagre 

Roadmap to Future 

As the global biotech industry is witnessing a surge in 

| 31 

players, competitive 

markets, and 

technological 

In the coming 

advancements, FBL 

years, FBL aims to 

has identified the 

become a holistic 

milestones that it 

intends to achieve over nutraceutical 

the next few years. It ingredient 

has broadly classified manufacturer, 

the goals in three through developing, 

directions: 

manufacturing and 

commercializing 

Product Portfolio micronutrients 

Expansion: FBL required for human 

intends to diversify its and animal nutrition 

portfolio to include a 

wide range of 

nutraceutical 

ingredients such as antioxidants and smart minerals that are 

microencapsulated for added benefits. 

International Collaborations: It continues to make 

determined efforts to widen its footprint of Vitamin D3 

across geographies through engagements established across 

six continents. To evolve as a key player in the 

nutraceuticals space, FBL has designed the roadmap to 

expand its portfolio through distribution agreements, joint 

ventures, and acquisitions. 

Micronutrient Space: FBL has envisaged various 

synergistic opportunities to create a formidable range of 

value-added nutritional ingredients, thus widening overall 

product offerings to cater to the pressing issue of 

micronutrient deficiency across the globe. 

FBL’s Associations 

Vitamin D Guru: FBL’s public awareness initiative is a 

digital platform to enhance knowledge about the 

significance of Vitamin D for health and wellness. 

Vitamin Angels: FBL contributes towards Vitamin Angels’ 

activities in the field of micronutrient deficiency in women 

and children in developing countries. 

National Association for the Blind (NAB): FBL not only 

contributes towards corneal transplants, squint correction 

surgeries, educational Braille kits and grant for Diploma in 

Special Education course, but also integrates NAB’s 

members with its internal activities for employee 

engagement. 

APRIL 2019 |

Healthcare Predictions 

FUTURE 

PREDICTIONS 

Of 

ELECTRONIC 

HEALTH 

RECORDS, 


& 

BEYOND 

About the Author 

Kumar Subramaniam, Founder & CEO at 

75Health 

Kumar Subramaniam has always believed 

and used technology as the means to 

improve the quality of business 

processes and enhance people's life. He 

conceptualized the innovative EMR 

Software with the objective of digitalizing 

crucial medical records and empowering 

medical practices to achieve the best 

care delivery. He leverages technology to 

achieve business objectives while serving 

the community better. 

Alot of changes and 

innovations have been 

occurring in the 

healthcare sector since the recent 

decades. Increased 

personalization in healthcare and 

increased understanding of 

patients’ role in achieving 

success of their own well-being 

is headed to a tipping point. 

Today, in addition to patient 

care, management of patient 

experience plays a vital role in 

the healthcare ecosystem. 

With the advent of medical 

information systems such as the 

electronic health record software 

and practice management 

software, a lot of unprecedented 

changes have taken place in 

clinical and administrative 


aspects of modern healthcare 

facilities and physician practices. 

The Transition to Electronic 

Health Records 

Globally, there has been a wide 

understanding about the virtues of 

the electronic health record and 

how it transforms the way 

healthcare is provided. Increasing 

adoption of the EHR is proof 

enough to emphasize the fact that it 

has become an integral part of the 

healthcare setting. 

The EHR landscape has had 

tremendous impact, thanks to the 

stringent industry standards and 

regulatory requirements such as 

HIPAA. Moreover, incentives to 

providers have also augured well 

with the increase in EHR adoption. 

What Does the Future Hold for 

the EHR Software? 

Although EHRs have been around 

since long, they are seen to have 

still a long way to go. As the 

medical industry switches over 

from the traditional volume-based 

reimbursement model to 

quality-based model, EHRs will be 

focusing more on value-based care, 

assisting providers to skillfully 

manage their patients’ health in the 

most optimal way. 

Understanding the following EHR 

trends in the coming years will 

enable practices to be prepared for 

facing unique needs and delivering 

the best possible care: 

• Ease of use and searchability 

o EHRs will be more easily 

searched, organized, and used – 

enabling full interaction with 

patients 

• Interoperability and Integration 

o The ability of EHR Systems to 

integrate with other health 

information systems will increase 

• Accessibility 

o Vendors will ensure that EHRs 

are more accessible to not only 

multi-facility networks and 

hospitals but also to all types of 

clinical practices regardless of 

size 

• Standardization 

o With stricter regulations and 

standardization of the EHR 

features and data, overall 

accuracy and reliability of the 

EHR System will increase 

manifold 

• Changing Dynamics 

o AI and virtual assistants will 

become more powerful and 

accessible, making their entry 

into health IT – this will help 

mitigate issues, if any, with the 

EHR Software 

The EHR System and Healthcare 

Delivery Connect 

Managing patient health records is 

rendered smooth and effective, thanks 

to the innovative EHR Software. Using 

computer software and hardware for 

the application of data processing 

ensures easy and accurate storing, 

sharing, and retrieval of medical 

information. It also makes it possible 

to utilize this information for effective 

communication and information-based 

decision making. 

Networking the computers and 

communication attributes effectively 

facilitates efficiently moving critical 

health information. This results in 

increased ability to deliver efficient, 

better care. 

Choosing the Right Fit for Your 

Practice 

EHR Software has attained an 

indispensable position in the 

healthcare sector. While choosing 

the EHR solution diligently and 

perfectly results in providers being 

facilitated to deliver better care 

quality and enhance practice 

efficiency, a wrong selection would 

lead to significant disruption to 

regular practice activities and 

continued difficulty all along the 

course of use of the software. 

As EHRs lend themselves to be 

customized according to specific 

practice needs, it is essential to first 

go through the various features and 

get complete demo of each solution 

prior to deciding which one to buy. 

With cloud being considered the 

future of computing and as today’s 

consumers are more inclined 

toward using mobile devices, 

cloud-based mobile EHR is set to 

become more dominant among 

EHR Software service providers 

and practitioners in the future. 

In the changing healthcare 

scenario, EHRs will certainly 

continue to play the role of the 

driving force in its evolution. Our 

goal is transforming the healthcare 

sector using digital technologies 

and empowering the healthcare 

fraternity to raise the bar of quality 

and efficiency several notches up. 


| 33

Pharma Trends 

Pharmaceutical 

Top 

Trends to Watch Out in 



Indian pharmaceutical industry is growing with an impressive pace for last couple of years and is expected to be in 

the top 10 global markets in value terms by 2020. The industry is progressing with a compounded annual growth 

rate (CAGR) of 15 percent over the last ve years and is adopting new business models to serve its targeted audience 

faster, and better. Good economic growth, high burden of diseases, improvement in healthcare infrastructure and 

increased awareness have tipped to be the reasons behind such optimistic projections. 

However, there are many areas on which any pharmaceutical company should look into- such as organ-on-chip, 3D 

Bio-printing, AI, and Antibiotics Discovery. Ignoring such vital areas can otherwise can hinder the growth prospects of 

pharmaceutical industry. 


| 35

3D Bio-printing 

Every year thousands of people lose their life due to 

organ failure. Many times even after being nancially 

capable, people do not receive organs at the right 

time as there is a wide gap between the growing 

demand of organs v/s number of registered donors 

in the industry. Usage 3D bio-printing thus many see 

as a solution for tackling this critical problem. In bioprinting, 

experts use patients own living cells to 

reproduce organs to reduce the risk of rejecting cells. 

T h i s f u r t h e r l o w e r t h e r i s k o f t a k i n g 

immunosuppressant drugs which are needed after 

organ transplant and many times causes trouble for 

the patients in terms of loss of appetite, nausea, 

vomiting, increased hair growth, and hand 

trembling. Moreover, transplantation using bioprinting 

only involves only one individual that needs 

to be operated on and hence, lowers the number of 

people need to be hospitalized during critical 

procedures. 

Many believe that organs made form bio-printing 

can also be used for drug discovery and testing, tissue 

engineering, research and study. These are the 

reasons why pharmaceuticals companies and 

hospitals are looking towards 3D bio-printing with an 

array of hope. It is mainly used for the creation and 

transplantation of several tissues including multilayered 

skin, heart tissue, cartilaginous structures, 

bone, vascular grafts, and tracheal splints. 

It can also help pharmaceutical companies in 

reducing overall cost associated with drug 

manufacturing once get transformed from an 

experimental stage to a fully functional mode. 

Increasing R&D expenditure, availability of venture 

capital, and government grants are fuelling the 

growth of 3D bio-printing. It is expected that 3D bioprinting 

market will reach USD 2.6 billion by 2024. 

Organs-on-chips 

Limitations of current planar, animal models and 

static cell culture system affect the drug discovery 

process to a larger extent. Many times it leads to 

increased drug failure rates which even cost 

pharmaceuticals companies billions of dollars. 

Moreover, many human diseases are still not 

modelled accurately using 'in vitro' process and thus 

hinder the growth in therapy development. 

Shortcomings of these models started a debate in the 

pharmaceutical vertical to develop a more 

physiological model relevant to human organs and 

thus lead to the growth of organs-on-chips. 

Organ-on-chip offers a wide range of applications 

such as phenotypic screening, diseases modelling, 

and patient stratication. Scientists believe that 

organs-on-chips have huge potential to make the 

drug discovery process efcient and faster as its 

microchips contain living cells which can mimic 

processes in the body such as peristalsis, breathing 

and infection. Such chips are tiny devices that imitate 

the structure, physiology and function of human 

organs. Researchers have represented over two 

dozen organs in on-chip systems, famously includes- 

Lung, Heart, Kidney, Artery, Skin. Some are even 

working to imitate a human-on-chip as well. 

While there is a lot of scepticism existed behind 

organs-on-chips some six to seven years ago, many 

pharmaceutical companies are now working towards 

it in a full-edged mode and embraced this concept 

into their business model as well. Market researchers 

predicts that organs-on-chip eld which was valued 

only at $5 million in 2016 will witnessed a meteoric 

rise in coming years and is expected to reach $170 

million by 2023. This industry will grow with a CAGR 

of 63.2% from 2017 to 2023, researchers predict. 


New Antibiotics Discovery 

Antibiotic resistant bacteria- superbug led to the 

death of more than 700,000 people all across the 

world. And, if UK government is to be believed, this 

number will dramatically jump up to 10 million by 

2050; if necessary steps not taken in the arena of new 

antibiotic discovery. Experts believe irresponsible 

prescription of antibiotics even for the normal cases, 

and increased usage of antibiotics in farming 

accelerating the rate of bacterial mutation, rendering 

them to resistant to drug with alarming pace. 

On the other hand, antibiotic discovery has been a 

much ignored area amongst the researchers. Most of 

the pharmaceutical companies are more inclined 

towards researching and developing drugs that are 

more “economically feasible”. This is the reason the 

last novel antibiotic classes was introduced some 

thirty years ago. 

However, with the growing need to tackle the menace 

of superbug, beneciary reforms in the legislation 

and increased investment in antibiotic researchmany 

organizations are now working day-in day-out 

to discover new antibiotics. 

In 2015, a group of scientists made a breakthrough 

in the antibiotics vertical with the discovery of 

Teixobactin, a powerful antibiotics class that has the 

potential to withstand the development of bacterial 

resistance against it. 

Increased Adoption of AI 

Developing a drug is a time consuming and 

e x p e n s i v e t a s k . T h e c u r r e n t p r o b l e m o f 

pharmaceutical industry is that nine out of 10 drugs 

fail to make it to pre-registration stage due to their 

poor absorption, distribution, metabolism, or 

excretion (ADME). 

In silico (on a computer) drug design, an innovative 

technique based on AI can help pharmaceutical 

companies to reduce such a shocking drug failure 

ratio. Such techniques allow the mapping of drugs 

structures and targets that can lead to a more 

successful drug development without costly scientic 

development. 

Another area of AI which is widely becoming popular 

is- advanced analytics. Every day thousands of 

journals and research paper get published on 

various prominent research institutes. Genius minds 

from across the globe sweat all through the years to 

create something concrete but unable to gain any 

insights form others research concerning to similar 

set of problems. Analytics has solved such problem. It 

process vast amount of scientic data and help 

pharmaceutical companies to develop drug at much 

faster pace by predicting the properties of new drug 

candidate in advance. This is the reason many 

companies now-a-days using AI to predict risks and 

their drivers to enable preventive maintenance and 

remediation of the drugs. 

In 2018, malacidins, a new family of antibiotics were 

discovered. However it is currently being in its nascent 

stage, but one can witness an increasing trend 

towards discovering new antibiotic class among the 

scientists community. 

- Shruti Jambhale 


| 37

Nucleome Informatics 

Unraveling the Genomes for a Better Future 

been regularly working on sequencing of cancer genomes 

and human exomes. Wildlife and plant genome sequencing 

and populations genomics is another area of interest where 

it provides NGS services regularly. The last six years have 

seen the company assemble 18 plants, 9 animals, 5 insects, 

and over 100 microbial genomes and analyzed human 

genome and exome sequencing data (4580 samples by Jan 

2019). It was also involved in prestigious sequencing 

projects like Mango, Pomegranate, Tiger, Indian Wild Dog, 

Leopard and Insect genome sequencing programs. It also 

offers cfDNA Sequencing and Cell line genome sequencing 

services. 

The Insightful Minds 

The company is a resultant of three genius minds coming 

together. 

(From Left to Right) 

Dushyant Singh Baghel, MD & CEO 

Bipin Kumar, Co-founder & VP 

Abhishek Tripathi, Co-founder & VP 

Nucleome Informatics is well regarded in the Life 

sciences industry for its expertise in de novo 

genome sequencing of larger genomes using 

hybrid assembly approach. Pharma companies and hospitals 

have been using Nucleome’s genome resequencing, exome 

sequencing and targeted resequencing services quite often. 

Nucleome plays a major role by providing Genomics and 

Bioinformatics analysis support for scientists working in 

the field of genomes, transcriptomes, metagenomes, and 

epigenomes research. Nucleome’s flagship product includes 

software DrSeq for RNA sequence analysis software, DrSeq 

Genome Survey and Big Data Decoder server specially 

designed for NGS analysis. Nucleome also has pipelines for 

Exome, Metagenome, transcriptome and amplicon datasets 

developed in-house. It has a variety of projects involving 

discovery of SNP markers by resequencing of human 

samples and identifying the complete Genetic makeup of 

the following organisms like, Buffalo, Pomegranate, 

Mango, Pigeon Pea, Mosquito, Dhole, Rice varieties, Indian 

Bengal Tiger, Great Indian Bustard, Eggplant Borer, etc. 

Distinguished Services 

Nucleome has successfully completed many significant 

plants, animals and microbial de novo genomes and has 

Dushyant Singh Baghel, Founder, MD and CEO hold an 

MS in Biotechnology from Bharathiar University and 

executive education in management from Indian School of 

Business, Hyderabad. He carries twelve years of experience 

in sequencing and assembly of genomes. A self-motivated 

person with true qualities of entrepreneurship and 

leadership, he started the company in the year 2012 with his 

partners and Co-founders Abhishek Tripathi and Bipin 

Kumar. 

Abhishek Tripathi, VP - R&D and Operations with an MS 

in Biotechnology has an experience of twelve years in 

Genomics Industry. 

Bipin Kumar, VP - Corporate Sales with an MS in 

Biotechnology has an experience of thirteen years in 

Genomics and diagnostics Industry. 

With a good understanding of Genomics market in India 

and their experience, they laid the foundation for 

Nucleome. Under the leadership of the founders Dushyant 

Singh Baghel, Bipin Kumar and Abhishek Tripathi, the 

team has designed and developed software for data 

analysis, assembled various genomes, completed more than 

500 Genome and Transcriptome projects in a span of 6 

years. Currently Nucleome is being considered as India’s 

fastest growing genomics and bioinformatics solution 

provider. 


1T 

HE 


PHARMA & 

L FE SCIENCES 


Hard Work is all it takes to Succeed 

Nucleome has invested its entire seed funding in building a 

well-equipped laboratory with sophisticated wet lab 

instruments and servers like BigData Decoder which are 

specially designed for next generation sequencing data 

analysis along with NGS analysis pipelines on online cloud 

servers like Google genomics, Amazon Web Server and 

DNA nexus. 

It has successfully completed various projects in association 

with various International organizations like CNRGV 

(France), Fasteris SA (Switzerland), Koppert Biological 

Systems (The Netherlands), Cold Spring Harbor Laboratory 

(USA), McDonnell Genome Institute, (USA), University of 

California (USA), Yale University (USA), New York 

Genome Center (USA), Washington University(USA), The 

Queensland Alliance for Agriculture and Food 

Innovation(Australia) and Indian institutes like CCMB, 

CIBA, IHBT, NRCP, NRCPB, ILS and NDDB. Nucleome 

has also built a sound association with all the major 

institutes under ICAR, CSIR, DBT and various hospitals 

including Tata Memorial Hospital Mumbai and private 

organisations like ITC and Beej Sheetal Seeds. 

Nucleome was awarded ‘India’s 20 Most Promising 

Pharma & Life Science Technology Solution Provider 

Companies 2016’ by a leading magazine. 

Using Nucleome’s services researchers have published 

several Research Papers. 

Paper in the field of Animal Genomics: 

• The Cuon Enigma: Genome survey and comparative 

genomics of the endangered Dhole 1 (Cuon alpinus) in 

bioRxiv 

• High coverage genome sequencing and identification of 

genomic variants in Bengal tiger (Panthera tigris tigris) 

in bioRxiv 

• Genome Plasticity in Cultured Leishmania donovani: 

Comparison of Early and Late Passages in Frontiers in 

Microbiology 

• RNA-Seq Revealed Expression of Many Novel Genes 

Associated With Leishmania do no vani Persistence and 

clearance in the Host Macrophage in Frontiers in 

Cellular and Infection Microbiology 

Papers in the field of Agri Genomics: 

• Analysis of DNA methylome and transcriptome 

profiling following Gibberellin A3 (GA3) foliar 

application in Nicotiana tabacum L. in Indian Journal 

of Plant Physiology 

• Identification of candidate pathogenicity determinants of 

Rhizoctonia 

solani AG1-IA, 

which causes 

sheath blight 

disease in rice in 

Current Genetics 

of Springer 

Nature 

• Alterations in rice 

chloroplast 

integrity, 

photosynthesis 

Company’s expertise 

lies in Sequencing 

and Analysis of de 

novo genome using 

hybrid assembly 

approach, 

Transcriptome, 

and genome 

resequencing data 

and metabolome associated with pathogenesis of 

Rhizoctonia solani in Scientific Reports 

• Sequencing, Denovo Assembly, Functional Annotation 

and Analysis of Phyllanthus amarus Leaf Transcriptome 

Using the Illumina Platform in Frontiers in Plant 

Science 

• Analysis of high iron rice lines reveals new miRNAs 

that target iron transporters in roots in Journal of 

Experimental Botany 

Lapping up the Opportunities 

The Pharma and life science industry is bustling with ideas 

and applications. The increasing application of genomics in 

biotech and pharmaceutical research and development has 

created a huge commercial market for sequencing and 

bioinformatics worldwide. The explosive growth of 

biological techniques necessitates the acquisition, 

processing, analysis, and integration of the data. These 

immense amounts of data are generated by the experiments 

as diverse as genomics, cloning, expression analysis, 

genotyping, cellular analysis and others. Many young 

entrepreneurs are looking at it as an opportunity for new 

startups. The founders advise them saying “Dare to 

dream…..Follow your dream….Live your dream…..Strive 

hard to achieve your dream.” 

For a Better Future 

Nucleome aims at a healthier future through revolutionary 

genetic analysis solutions. It is committed to generating 

rapid, appropriate and high-quality results which can create 

a great difference in research projects. 

Nucleome’s focus has always been in the field of Plant, 

Animal and Human Genomics and is planning to strengthen 

its position in this field. It has planned to raise its SeriesA 

funding to expand its infrastructure by building India’s 

largest genomics and supercomputing bioinformatics 

facility. It aims to fund and propel its Population genomics 

program to sequence 10,000 human genomes and 100,000 

exomes of various cancer and diabetics patients in India. 


| 39

The 10 Most Recommended Pharma & Life Sciences Solution providers in 2019

Create successful ePaper yourself

Delete template?

Save as template?